Bowel Disease Patients Carry Higher Risk of Thromboembolic Events: UT Houston

Thromboembolic EventsResearchers at the University of Texas in Houston have reavealed in a new study that thromboembolic events are up 27% in the past decade among patients with inflammatory bowel disease (IBD). The number of IBD patients rose from 34,300 to 58,468, and the rate of thromboembolic events among those IBD patients also rose from 5.65% in 2000 to 7.17% in 2009, which is a 27% increase.The findings were presented by  Anahita Dua, MD, a postdoctoral research fellow at the University of Texas in Houston, at the American College of Surgeons 2013 Annual Clinical Congress.

“Thromboembolic disease is not a new finding in patients with IBD; however, our study highlights that it is not just venous disease that we need to be focused on,” said Dr. Dua. “Patients who have IBD are at risk for acute coronary syndrome, stroke, mesenteric ischemia, and deep vein thrombosis. With the rising incidence of these events, we need to be more aware of these patients.”

One important finding is that the rate of arterial events was nearly double of venous events. Research analyzed 461,415 patients with IBD and more than 6% had thromboembolic events, including 3.96% with arterial events and 2.40% with venous events. Previous studies have highlighted the venous complications of IBD patients but the arterial risk has not been well described, according to Dr. Dua.

Comparing IBD patients with thromboembolic events to those who without it, patients were older (average 62 vs 49 years old), more likely to be male (46% vs 42%), have been admitted emergently (86% vs 77%), have been transferred from another institution (9% vs 4%), and they were less likely to have private insurance (35% vs 50%).

“The next step is to examine factors in patients with IBD that put them at higher risk for thromboembolic events. Then we want to see if any of these factors are potentially modifiable, or are targets for early intervention or prophylaxis, to enable physicians and patients to proactively take steps to reduce the incidence in this vulnerable population,” said SreyRam Kuy, MD, a vascular surgery fellow from the Medical College of Wisconsin.

About Chris Comish

Chris Comish
Chris Comish is the Publisher, President, and CEO of BioNews Texas. He is an influencer in the Texas biotech industry and guides the editorial and content direction of the publication.
Scroll To Top